We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

51 hedge funds and large institutions have $71.6M invested in Theriva Biologics in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

13% more funds holding

Funds holding: 45 → 51 (+6)

2% more capital invested

Capital invested by funds: $70.2M → $71.6M (+$1.37M)

0% less ownership

Funds ownership: 0% → 0% (-0%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
51
Holders Change
+6
Holders Change %
+13.33%
% of All Funds
1.34%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
10
Increased
7
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$1.25M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$571K
3
Deutsche Bank
Deutsche Bank
Germany
+$317K
4
VKH
Virtu KCG Holdings
New York
+$275K
5
BCM
Bluefin Capital Management
New York
+$190K

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$1.11M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$625K
3
BGA
Belmont Global Advisors
Texas
-$487K
4
Morgan Stanley
Morgan Stanley
New York
-$444K
5
Citadel Advisors
Citadel Advisors
Florida
-$95K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bluefin Capital Management
New York
$173K +$190K +9 New
FSA
27
Franklin Street Advisors
North Carolina
$169K – – –
Millennium Management
28
Millennium Management
New York
$145K +$84.6K +4 +133%
Wells Fargo
29
Wells Fargo
California
$145K +$127K +6 +600%
CS
30
Credit Suisse
Switzerland
$141K +$148K +7 New
UBS Group
31
UBS Group
Switzerland
$138K +$21.2K +1 +17%
State Street
32
State Street
Massachusetts
$123K – – –
LTFS
33
Ladenburg Thalmann Financial Services
Florida
$115K – – –
HighTower Advisors
34
HighTower Advisors
Illinois
$102K – – –
M&T Bank
35
M&T Bank
New York
$83K – – –
Creative Planning
36
Creative Planning
Kansas
$77K – – –
Jane Street
37
Jane Street
New York
$64K +$63.5K +3 New
Stifel Financial
38
Stifel Financial
Missouri
$60K – – –
Goldman Sachs
39
Goldman Sachs
New York
$57K +$63.5K +3 New
HLA
40
Hamilton Lane Advisors
Pennsylvania
$55K – – –
MWM
41
Mission Wealth Management
California
$53K – – –
WS
42
Wedbush Securities
California
$50K – – –
TDC
43
Thompson Davis & Co
Virginia
$46K – – –
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$34K +$42.3K +2 New
BA
45
BlackRock Advisors
Delaware
$31K – – –
Bank of America
46
Bank of America
North Carolina
$29K – – –
GC
47
Guggenheim Capital
Illinois
$29K – – –
BIM
48
BlackRock Investment Management
Delaware
$25K – – –
Fisher Asset Management
49
Fisher Asset Management
Washington
$24K – – –
CA
50
Corrado Advisors
New Jersey
$23K +$21.2K +1 New
1
2
3

TOVX Hedge Fund Activity: Q4 2015 in Review

51 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2015, worth a combined $71.6M — up 2% from $70.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TOVX positions and 4 closed out — a net gain of 6 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was William Blair & Company, adding an estimated $1.25M. The largest seller was EAM Investors, exiting entirely with an estimated $1.11M sold.

  • 51 institutional investors held Theriva Biologics (TOVX) as of Q4 2015, up from 45 in Q3 2015.
  • Funds reported $71.6M of Theriva Biologics stock for Q4 2015, up 2% quarter-over-quarter.
  • 10 funds opened new Theriva Biologics positions in Q4 2015 and 4 closed out, a net change of +6 holders.
  • The largest Theriva Biologics buyer in Q4 2015 was William Blair & Company, an estimated $1.25M added.
  • The largest Theriva Biologics seller in Q4 2015 was EAM Investors, an estimated $1.11M sold.

Based on aggregated 13F filings for Q4 2015.